CN101023955A - Medicine composition and use - Google Patents
Medicine composition and use Download PDFInfo
- Publication number
- CN101023955A CN101023955A CN200610008296.7A CN200610008296A CN101023955A CN 101023955 A CN101023955 A CN 101023955A CN 200610008296 A CN200610008296 A CN 200610008296A CN 101023955 A CN101023955 A CN 101023955A
- Authority
- CN
- China
- Prior art keywords
- quercetin
- weight portions
- pharmaceutical composition
- described pharmaceutical
- glucoside
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 28
- 239000000203 mixture Substances 0.000 title claims abstract description 24
- 229940079593 drug Drugs 0.000 title description 14
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 claims abstract description 44
- FVQOMEDMFUMIMO-UHFFFAOYSA-N Hyperosid Natural products OC1C(O)C(O)C(CO)OC1OC1C(=O)C2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 FVQOMEDMFUMIMO-UHFFFAOYSA-N 0.000 claims abstract description 41
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 claims abstract description 22
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 claims abstract description 22
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 claims abstract description 22
- 235000005875 quercetin Nutrition 0.000 claims abstract description 22
- 229960001285 quercetin Drugs 0.000 claims abstract description 22
- OVSQVDMCBVZWGM-IDRAQACASA-N Hirsutrin Natural products O([C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1)C1=C(c2cc(O)c(O)cc2)Oc2c(c(O)cc(O)c2)C1=O OVSQVDMCBVZWGM-IDRAQACASA-N 0.000 claims abstract description 21
- OVSQVDMCBVZWGM-QSOFNFLRSA-N quercetin 3-O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-QSOFNFLRSA-N 0.000 claims abstract description 21
- OVSQVDMCBVZWGM-SJWGPRHPSA-N Hyperin Natural products O[C@H]1[C@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-SJWGPRHPSA-N 0.000 claims abstract description 20
- OVSQVDMCBVZWGM-DTGCRPNFSA-N quercetin 3-O-beta-D-galactopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-DTGCRPNFSA-N 0.000 claims abstract description 20
- BBFYUPYFXSSMNV-UHFFFAOYSA-N quercetin-7-o-galactoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=C2C(=O)C(O)=C(C=3C=C(O)C(O)=CC=3)OC2=C1 BBFYUPYFXSSMNV-UHFFFAOYSA-N 0.000 claims abstract description 20
- 208000015181 infectious disease Diseases 0.000 claims abstract description 7
- 208000007107 Stomach Ulcer Diseases 0.000 claims abstract description 6
- 201000005917 gastric ulcer Diseases 0.000 claims abstract description 6
- 230000000144 pharmacologic effect Effects 0.000 claims abstract description 4
- 230000009471 action Effects 0.000 claims abstract description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 58
- KJXSIXMJHKAJOD-LSDHHAIUSA-N (+)-dihydromyricetin Chemical compound C1([C@@H]2[C@H](C(C3=C(O)C=C(O)C=C3O2)=O)O)=CC(O)=C(O)C(O)=C1 KJXSIXMJHKAJOD-LSDHHAIUSA-N 0.000 claims description 34
- GXMWXESSGGEWEM-UHFFFAOYSA-N isoquercitrin Natural products OCC(O)C1OC(OC2C(Oc3cc(O)cc(O)c3C2=O)c4ccc(O)c(O)c4)C(O)C1O GXMWXESSGGEWEM-UHFFFAOYSA-N 0.000 claims description 18
- KQILIWXGGKGKNX-UHFFFAOYSA-N dihydromyricetin Natural products OC1C(=C(Oc2cc(O)cc(O)c12)c3cc(O)c(O)c(O)c3)O KQILIWXGGKGKNX-UHFFFAOYSA-N 0.000 claims description 17
- 208000002399 aphthous stomatitis Diseases 0.000 claims description 13
- 208000007117 Oral Ulcer Diseases 0.000 claims description 9
- 208000014674 injury Diseases 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 9
- 239000002775 capsule Substances 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 206010053615 Thermal burn Diseases 0.000 claims description 5
- 238000011109 contamination Methods 0.000 claims description 5
- 238000002347 injection Methods 0.000 claims description 5
- 239000007924 injection Substances 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- -1 patch Substances 0.000 claims description 5
- 230000008733 trauma Effects 0.000 claims description 5
- 239000008187 granular material Substances 0.000 claims description 4
- 235000020357 syrup Nutrition 0.000 claims description 4
- 239000006188 syrup Substances 0.000 claims description 4
- 206010017553 Furuncle Diseases 0.000 claims description 3
- 238000009472 formulation Methods 0.000 claims description 3
- 239000000499 gel Substances 0.000 claims description 3
- 230000035876 healing Effects 0.000 claims description 3
- 239000012528 membrane Substances 0.000 claims description 3
- 239000002674 ointment Substances 0.000 claims description 3
- 239000000443 aerosol Substances 0.000 claims description 2
- 230000036592 analgesia Effects 0.000 claims description 2
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 230000003115 biocidal effect Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 abstract description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 7
- 208000002193 Pain Diseases 0.000 abstract description 6
- 230000036407 pain Effects 0.000 abstract description 6
- 241000894006 Bacteria Species 0.000 abstract description 5
- YLWQTYZKYGNKPI-HMGRVEAOSA-N 3,5,7-trihydroxy-2-[4-hydroxy-3-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]chromen-4-one Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=CC=C1O YLWQTYZKYGNKPI-HMGRVEAOSA-N 0.000 abstract description 4
- OVSQVDMCBVZWGM-QCKGUQPXSA-N isoquercetin Natural products OC[C@@H]1O[C@@H](OC2=C(Oc3cc(O)cc(O)c3C2=O)c4ccc(O)c(O)c4)[C@H](O)[C@@H](O)[C@@H]1O OVSQVDMCBVZWGM-QCKGUQPXSA-N 0.000 abstract description 3
- 206010061218 Inflammation Diseases 0.000 abstract description 2
- IKMDFBPHZNJCSN-UHFFFAOYSA-N Myricetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC(O)=C(O)C(O)=C1 IKMDFBPHZNJCSN-UHFFFAOYSA-N 0.000 abstract description 2
- YLWQTYZKYGNKPI-UHFFFAOYSA-N UNPD13421 Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=CC=C1O YLWQTYZKYGNKPI-UHFFFAOYSA-N 0.000 abstract description 2
- 230000004054 inflammatory process Effects 0.000 abstract description 2
- PCOBUQBNVYZTBU-UHFFFAOYSA-N myricetin Natural products OC1=C(O)C(O)=CC(C=2OC3=CC(O)=C(O)C(O)=C3C(=O)C=2)=C1 PCOBUQBNVYZTBU-UHFFFAOYSA-N 0.000 abstract description 2
- 235000007743 myricetin Nutrition 0.000 abstract description 2
- 229940116852 myricetin Drugs 0.000 abstract description 2
- NQYPTLKGQJDGTI-FCVRJVSHSA-N hyperoside Natural products OC[C@H]1O[C@@H](OC2=C(Oc3cc(O)cc(O)c3[C@H]2O)c4ccc(O)c(O)c4)[C@H](O)[C@@H](O)[C@H]1O NQYPTLKGQJDGTI-FCVRJVSHSA-N 0.000 abstract 1
- 230000001737 promoting effect Effects 0.000 abstract 1
- 230000000472 traumatic effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 18
- 208000024891 symptom Diseases 0.000 description 18
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 230000010354 integration Effects 0.000 description 11
- 238000012360 testing method Methods 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 208000025865 Ulcer Diseases 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 231100000397 ulcer Toxicity 0.000 description 9
- 229920002472 Starch Polymers 0.000 description 8
- 230000000844 anti-bacterial effect Effects 0.000 description 8
- 230000003203 everyday effect Effects 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 239000013641 positive control Substances 0.000 description 8
- 239000008107 starch Substances 0.000 description 8
- 235000019698 starch Nutrition 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- 230000006378 damage Effects 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 230000000202 analgesic effect Effects 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 229920001353 Dextrin Polymers 0.000 description 5
- 239000004375 Dextrin Substances 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 229960000583 acetic acid Drugs 0.000 description 5
- 235000019425 dextrin Nutrition 0.000 description 5
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 5
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 5
- GYCKQBWUSACYIF-UHFFFAOYSA-N o-hydroxybenzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 description 5
- 210000002700 urine Anatomy 0.000 description 5
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 4
- 208000035143 Bacterial infection Diseases 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 4
- 208000000114 Pain Threshold Diseases 0.000 description 4
- 229920002125 Sokalan® Polymers 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 208000022362 bacterial infectious disease Diseases 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 229960001631 carbomer Drugs 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000002147 killing effect Effects 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 230000037040 pain threshold Effects 0.000 description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 239000012362 glacial acetic acid Substances 0.000 description 3
- 230000003908 liver function Effects 0.000 description 3
- 210000000214 mouth Anatomy 0.000 description 3
- 230000000306 recurrent effect Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 229960002668 sodium chloride Drugs 0.000 description 3
- 235000002639 sodium chloride Nutrition 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 239000001828 Gelatine Substances 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229920003091 Methocel™ Polymers 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 206010028034 Mouth ulceration Diseases 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229920001214 Polysorbate 60 Polymers 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229960003943 hypromellose Drugs 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 235000020374 simple syrup Nutrition 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- TWCMVXMQHSVIOJ-UHFFFAOYSA-N Aglycone of yadanzioside D Natural products COC(=O)C12OCC34C(CC5C(=CC(O)C(O)C5(C)C3C(O)C1O)C)OC(=O)C(OC(=O)C)C24 TWCMVXMQHSVIOJ-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- PLMKQQMDOMTZGG-UHFFFAOYSA-N Astrantiagenin E-methylester Natural products CC12CCC(O)C(C)(CO)C1CCC1(C)C2CC=C2C3CC(C)(C)CCC3(C(=O)OC)CCC21C PLMKQQMDOMTZGG-UHFFFAOYSA-N 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 239000006002 Pepper Substances 0.000 description 1
- HCBIBCJNVBAKAB-UHFFFAOYSA-N Procaine hydrochloride Chemical compound Cl.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 HCBIBCJNVBAKAB-UHFFFAOYSA-N 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 208000005946 Xerostomia Diseases 0.000 description 1
- 206010048245 Yellow skin Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000009172 bursting Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- PFOARMALXZGCHY-UHFFFAOYSA-N homoegonol Natural products C1=C(OC)C(OC)=CC=C1C1=CC2=CC(CCCO)=CC(OC)=C2O1 PFOARMALXZGCHY-UHFFFAOYSA-N 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 description 1
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 1
- 235000008696 isoflavones Nutrition 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 235000005739 manihot Nutrition 0.000 description 1
- 229940074869 marquis Drugs 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- VBUNOIXRZNJNAD-UHFFFAOYSA-N ponazuril Chemical compound CC1=CC(N2C(N(C)C(=O)NC2=O)=O)=CC=C1OC1=CC=C(S(=O)(=O)C(F)(F)F)C=C1 VBUNOIXRZNJNAD-UHFFFAOYSA-N 0.000 description 1
- 229960001309 procaine hydrochloride Drugs 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- DKVBOUDTNWVDEP-NJCHZNEYSA-N teicoplanin aglycone Chemical compound N([C@H](C(N[C@@H](C1=CC(O)=CC(O)=C1C=1C(O)=CC=C2C=1)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)OC=1C=C3C=C(C=1O)OC1=CC=C(C=C1Cl)C[C@H](C(=O)N1)NC([C@H](N)C=4C=C(O5)C(O)=CC=4)=O)C(=O)[C@@H]2NC(=O)[C@@H]3NC(=O)[C@@H]1C1=CC5=CC(O)=C1 DKVBOUDTNWVDEP-NJCHZNEYSA-N 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 210000005182 tip of the tongue Anatomy 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention provides a medicine composition. Said medicine composition uses hyperoside, myricetin, quercetin, isoquercetin, quercetin-3-0-alpha-L-rhamnopyr anosy (1-6)-beta-D-galactopyranoside and quercetin-3'-glucoside as active components, and the obvious pharmacological action of resisting inflammation, resisting bacteria, stopping pain and promoting union for curing the diseases of stomatocase, burn, scaled, gastric ulcer and traumatic infection, etc.
Description
The present invention relates to a kind of pharmaceutical composition, the invention still further relates to the purposes of this pharmaceutical composition.
Hyperin (hyperin), ampelopsin (myricetin), Quercetin (quercetin), isoquercitrin (isoquercetin), Quercetin-3-O-α-L-rhamnose (1-6)-β-D-galactose (quercetin-3-O-α-L-rhamno-pyranosy (1-6)-β-D-galactopyranoside), Quercetin-3`-glucoside (quercetin-3`-glucoside) all are to extract the known compound that obtains from Flos abelmoschi manihot, and their structural formula is as follows respectively:
The Quercetin ampelopsin
Hyperin Quercetin-3`-glucoside
Quercetin-3-O-α-L-rhamnose (1-6)-β-D-galactose isoquercitrin
Above-mentioned six kinds of chemical compounds are made up according to a certain percentage, its The pharmacological results shows, the rabbit stomatocace model that said composition is caused injury at Dichlorodiphenyl Acetate, three kinds of methods of mechanical damage and bacterial infection are set up, obvious treatment effect (P＜0.05) is all arranged, and drug effect continues to help the reparation of ulcer.Antibacterial tests result shows that this pharmaceutical composition all has stronger killing or inhibitory action to Gram-positive and the gram negative bacteria in the experiment, and antimicrobial spectrum is comparatively extensive.The analgesic test is the result show, said composition heavy dose (500mg/kg), and middle dosage (250mg/kg) can obviously improve the mice pain threshold; 500mg/kg obviously reduces the mouse writhing number of times that is brought out by glacial acetic acid (0.6%), illustrates that it has certain analgesic activity.Test shows that also the mice auricle swelling that said composition 500mg/kg xylol causes has good inhibitory effect.Wherein one of composition of said composition isoquercitrin (isoquercetin) is the isoflavone aglycone constituents of Quercetin, with hyperin, Quercetin-3 '-glucoside, Quercetin-3-O-α-L-rhamnose (1-6)-β-D-galactose all produce aglycon quercetin in vivo after hydrolysis, thereby the synergism of performance and Quercetin, strengthen effects such as its antiinflammatory, analgesia, clinically oral ulcer, gastric ulcer, burn and scald, trauma infection contamination (furuncle) have been had the good curing effect.Thereby finished the present invention.
An object of the present invention is to provide a kind of rabbit stomatocace model effect that treatment acetic acid is caused injury, three kinds of methods of mechanical damage and bacterial infection are set up that has, Gram-positive and gram negative bacteria in the experiment all had stronger killing or inhibitory action, heavy dose of (500mg/kg), middle dosage (250mg/kg) can obviously improve the mice pain threshold; 500mg/kg obviously reduces the mouse writhing number of times that is brought out by glacial acetic acid (0.6%), the pharmaceutical composition of the effect of the mice auricle swelling that inhibition dimethylbenzene causes.
Another object of the present invention provides the purposes of this pharmaceutical composition at the medicament of preparation treatment oral ulcer and gastric ulcer.
Another purpose of the present invention provides this pharmaceutical composition injures the medicament of trauma infection contamination at preparation treatment burn and scald purposes.
A further object of the present invention provides this pharmaceutical composition and is made into various oral and exterior-applied formulations commonly used, comprises the preparation method of tablet, capsule, granule, injection, oral liquid, syrup, aerosol, paster agent, ointment, gel, patch, membrane etc.
Pharmaceutical composition of the present invention is made active component with the component that contains following consumption:
Hyperin 15～35 weight portions
Ampelopsin 1～15 weight portion
Quercetin 1～15 weight portion
Isoquercitrin 1～14 weight portion
Quercetin-3-O-α-L-rhamnose (1-6)-β-D-galactose 10～25 weight portions
Quercetin-3`-glucoside 8～25 weight portions
The preferable amount of active constituent is:
Hyperin 20～32 weight portions
Ampelopsin 4～13 weight portions
Quercetin 8～14 weight portions
Isoquercitrin 6～12 weight portions
Quercetin-3-O-α-L-rhamnose (1-6)-β-D-galactose 12～24 weight portions
Quercetin-3`-glucoside 15～22 weight portions
The optimum amount of active constituent is in the pharmaceutical composition of the present invention:
Hyperin 30 weight portions
Ampelopsin 9 weight portions
Quercetin 12 weight portions
Isoquercitrin 10 weight portions
Quercetin-3-O-α-L-rhamnose (1-6)-β-D-galactose 18 weight portions
Quercetin-3`-glucoside 21 weight portions
Pharmaceutical composition of the present invention also contains excipient pharmaceutically commonly used, and these excipient are according to the difference of dosage form and difference.When pharmaceutical composition of the present invention was made into tablet, the excipient that it contains had: diluent, as: starch, dextrin, lactose etc.; Wetting agent or binding agent, as: water, ethanol, starch slurry, dextrin, gelatine size, low-substituted hydroxypropyl cellulose, polyvinylpyrrolidone, Polyethylene Glycol etc.; Disintegrating agent, as: dry starch, gas-producing disintegrant, microcrystalline Cellulose; Lubricant, as: Pulvis Talci, magnesium stearate etc.When pharmaceutical composition of the present invention was made into capsule, the excipient that it contains had: diluent, as: starch, dextrin, lactose, magnesium oxide, magnesium carbonate etc.; Wetting agent or binding agent, as: water, ethanol, starch slurry, dextrin, gelatine size, low-substituted hydroxypropyl cellulose, polyvinylpyrrolidone, Polyethylene Glycol etc.; Disintegrating agent, as: dry starch, gas-producing disintegrant, microcrystalline Cellulose etc.; And select gelatin hard softgel shell or soft capsule shell for use.When pharmaceutical composition of the present invention was made into injection, the excipient that it contains had: solubilizing agent, as, tween 80, glycerol etc.; Suspensoid, as: hydroxy methocel, polyvinylpyrrolidone, methylcellulose etc.; Antioxidant, as: sodium sulfite, sodium pyrosulfite, sodium thiosulfate etc.; Osmotic pressure regulator is as sodium chloride or glucose etc.; The additives that ease the pain, as: benzyl alcohol, procaine hydrochloride etc.When pharmaceutical composition of the present invention was made into syrup, the excipient that it contains had: aqueous sucrose solution, correctives; Suspending agent is as hydroxy methocel, polyvinylpyrrolidone, methylcellulose etc.; Antiseptic is as ethyl hydroxybenzoate or methyl hydroxybenzoate, propylene glycol, benzoic acid, sorbic acid etc.
The rabbit stomatocace model that pharmaceutical composition of the present invention is caused injury at Dichlorodiphenyl Acetate, three kinds of methods of mechanical damage and bacterial infection are set up all has obvious treatment effect (P＜0.05), and drug effect continues to help the reparation of ulcer.Antibacterial tests result shows that this pharmaceutical composition all has stronger killing or inhibitory action to Gram-positive and the gram negative bacteria in the experiment, and antimicrobial spectrum is comparatively extensive.The analgesic test is the result show, said composition heavy dose (500mg/kg), and middle dosage (250mg/kg) can obviously improve the mice pain threshold; 500mg/kg obviously reduces the mouse writhing number of times that is brought out by glacial acetic acid (0.6%), illustrates that it has certain analgesic activity.Test shows that also the mice auricle swelling that said composition 500mg/kg xylol causes has good inhibitory effect.Clinically oral ulcer, gastric ulcer, burn and scald, trauma infection contamination (furuncle) had the good curing effect.
The effective dose of pharmaceutical composition of the present invention and using method are: oral, and every day 1～2 time, each 1～2 tablet of tablet (or 2～4 capsules; 1～2 oral liquid); Injection once a day, each 1～2; External every day 2～3 times, each 1～2 membrane, or 1～2 paster agent, or be sprayed on the affected part every day repeatedly, or be applied to the affected part every day repeatedly, or paster is spread on the affected part; Below by the test above-mentioned these effects are further confirmed.
Experimental example 1: the drug action of two kinds of rabbit oral ulcer models that Dichlorodiphenyl Acetate is caused injury, bacterial infection is set up.
Experimental result sees Table 1,2.
Table 1 different dosing time acetic acid causes ulcer and dwindles percentage rate (%)
| Group | Administration 3 days | Administration 6 days | Administration 9 days |
| Blank | 12.7 | 35.6 | 64.6 |
| Positive control | 34.3 | 58.7 | 88.0 |
| The heavy dose of group of pharmaceutical composition | 36.1 | 64.0 | 87.1 |
| Dosage group in the pharmaceutical composition | 24.7 | 51.6 | 73.6 |
| The pharmaceutical composition small dose group | 25.6 | 48.2 | 72.5 |
Table 2 different dosing time antibacterial causes ulcer and dwindles percentage rate (%)
| Group | Administration 2 days | Administration 3 days | Administration 4 days | Administration 5 days | Administration 6 days | Administration 7 days | Administration 8 days |
| Blank | 15.8 | 34.7 | 51.2 | 71.8 | 82.9 | 87.6 | 94.2 |
| Positive control | 36.2 | 51.8 | 84.3 | 96.9 | 98.2 | 100.0 | 100.0 |
| The heavy dose of group of pharmaceutical composition | 35.8 | 52.9 | 83.9 | 95.2 | 97.8 | 100.0 | 100.0 |
| Dosage group in the pharmaceutical composition | 16.2 | 33.2 | 67.8 | 92.3 | 97.8 | 98.1 | 99.0 |
| The pharmaceutical composition small dose group | 5.9 | 14.8 | 51.0 | 72.9 | 85.4 | 90.2 | 95.3 |
The pharmacological results shows that this pharmaceutical composition all has obvious treatment effect (P＜0.05) to two kinds of rabbit oral ulcer models.
Experimental example 2: adopt the plate doubling dilution, clinical isolating 80 strain antibacterials have been carried out the antibacterial bacteriostatic test.The results are shown in Table 3.
The MIC of table 3 pair 80 strain antibacterials measures
| Antibacterial | The strain number | Medicine | MIC scope (mg/ml) | MIC50 (mg/ml) | MIC90 (mg/ml) |
| Staphylococcus aureus | 20 | The pharmaceutical composition positive control | 0.03125-4 0.25-16 | 0.5 4 | 4 16 |
| Staphylococcus epidermidis | 10 | The pharmaceutical composition positive control | 0.0625-8 0.125-16 | 1 1 | 4 8 |
| Escherichia coli | 20 | The pharmaceutical composition positive control | 0.015625-8 0.25-16 | 0.5 4 | 4 16 |
| Bacillus pyocyaneus | 20 | The pharmaceutical composition positive control | 1-64 4-64 | 8 16 | 64 64 |
| Bacillus proteus | 10 | The pharmaceutical composition positive control | 0.25-16 0.0625-4 | 4 2 | 16 4 |
Antibacterial tests result shows that this pharmaceutical composition all has stronger killing or inhibitory action to Gram-positive and negative bacterium.
Experimental example 3: adopt hot plate method to measure the analgesic activity of this pharmaceutical composition.The results are shown in Table 4.
Table 4. pair mice hot plate causes the influence (n=20) of pain
| Group | Dosage (mg/kg) | Different time behind the medicine (second) pain threshold (s, X ± SD) | ||
| 90 | 120 | 150 | ||
| Blank | — | 18.7±4.62 | 19.2±3.75 | 18.9±3.82 |
| Positive control | 500 | 26.3±6.54 * | 24.2±5.11 * | 19.9±3.22 |
| The heavy dose of group of pharmaceutical composition | 500 | 29.3±7.56 * | 25.6±6.33 * | 21.8±4.26 |
| Dosage group in the pharmaceutical composition | 250 | 26.1±6.82 * | 24.3±3.60 * | 20.3±4.13 |
| The pharmaceutical composition small dose group | 125 | 20.9±4.33 | 20.8±4.67 | 19.8±5.69 |
*Compare P＜0.05 with blank
The result shows that this pharmaceutical composition has certain analgesic activity.
Below further confirm by the effect of clinical prerun this medicine composite for curing oral ulcer.
Take principle at random, observe 20 examples altogether, wherein 10 examples are organized in treatment, matched group 10 examples.And carried out clinical efficacy and safety investigation, now be summarized as follows:
One, case choice criteria
Observe patient's 20 examples altogether, all from being in hospital and the outpatient service patient, Western medicine diagnose is with reference to " the infections clinical research guideline of bursting in traditional Chinese medical science new drug treatment oral cavity "; Chinese medical discrimination standard reference " the clinical guidance principle of traditional Chinese medical science new drug treatment oral ulcer ".
Two, observation index
1. safety observation
(1) general body examination project
(2) blood, urine, stool routine examination inspection
(3) liver, renal function check, Electrocardioscopy
2. health giving quality observation
(1) related symptoms and sign are observed
(2) local disease is decreased not according to examining
(3) ulcer symptom and duration of seizure are observed
Three, observational technique
Random experiment is adopted in this research, by patient's sequence number of going to a doctor, meets and includes standard person in, all includes observation in.
The treatment group: the paster that pharmaceutical composition is made, usage: be affixed on the affected part, each 1～2, every day 1～2 time.5 days is a course of treatment; Observe two courses of treatment altogether.
Matched group: but meaning paster usage: be affixed on the affected part, each 1～2, every day 1～2 time.5 days is a course of treatment; Observe two courses of treatment altogether.
Four, efficacy determination
1. curative effect of disease
(1) clinical recovery: medication 3 days obviously alleviates with interior symptom, sign, and medication 5 days disappears with interior symptom, sign.
(2) produce effects: medication 5 days obviously alleviates with interior symptom, sign, and integration reduces 〉=70%.
(3) effective: medication 5 days alleviates with interior symptom, sign, and integration reduces 〉=30%.
(4) invalid: medication 5 days does not all have obvious improvement with interior symptom, sign, even increases the weight of, and integration reduces less than 30%.
2. recurrent aphtha symptom, sign curative effect determinate standard
(1) clinical recovery: individual event symptom, sign medication 5 days obviously alleviate with interior symptom, sign, and medication 5 days disappears with interior symptom, sign, and integration reduces 〉=95%.
(2) produce effects: individual event symptom, sign medication 5 days obviously alleviate with interior symptom, sign, and integration reduces 〉=70%.
(3) effective: individual event symptom, sign medication 5 days alleviate with interior symptom, sign, and integration reduces 〉=30%.
(4) invalid: individual event symptom, sign medication 5 days all do not have obvious improvement with interior symptom, sign, even increase the weight of, and integration reduces less than 30%.
Therapeutic index=[integrated value before (total mark value before the treatment-treatment back total mark value)/treatment] * 100%
Five, observed result
1. treatment group disease total effective rate 100.00%, cure-remarkable-effectiveness rate 80.00%; Matched group disease total effective rate 90.00%, cure-remarkable-effectiveness rate 70.00%; Learning processing (P＜0.05) two groups by statistics has significant difference, and the treatment group is better than matched group.
2. the Syndrome in TCM marquis treats forward and backward comparison, and significant difference (P＜0.05) is arranged.
3. the patient has all done blood, urine, liver function, renal function, Electrocardioscopy before and after treatment, and the result shows: Non Apparent Abnormality changes before the treatment, does not find untoward reaction and toxic and side effects.
Six, model case
Case 1: Zhao * *, man, 32 years old, cadre.
The main suit: aphtha of the mouth and tongue shows effect repeatedly and festers 2～3 years, and again because of the common cold heating causes profusely scorching hot pain, it is heavier to eat vinegar-pepper one-tenth thing recently, and dry stool is vexed.Thirsty insomnia, urine is fervid.Examine in the lip and a plurality of yellow-white depression speckles that differ in size of the two cheek thes tip of the tongue, edge blush, red tongue, yellow fur, rapid pulse.Integration before treating: 19 minutes.
Western medicine diagnose: stomatitis aphtha.
Tcm diagnosis: accumulation of heat in the heart and spleen type.
Be attached at the affected part through giving the pharmaceutical composition paster, each 2, every day 2 times, ulcer surface healing after 3 days, it is good to sleep, and diet increases, the stringy pulse red tongue, symptom disappears substantially.Have a medical check-up: blood, two is just conventional, and electrocardiogram, liver function, kidney merit five change, in the drug administration process and think and not any reaction occurs.Treat the back integration: 0 minute.Efficacy determination is: clinical cure.
Case 2: Lee * *, the woman, 37 years old, the cadre,
The main suit: there are 1.5～2mm ulcer not of uniform size, 2 places two buccals, oral cavity.This outbreak is surplus existing February.Lack of appetite is indigestion and loss of appetite, and it is not well to defecate, the urine yellow skin, and red tongue, white and thin fur, wiry and frequent pulse is slow unable.Integration is 15 minutes before treating.
Western medicine diagnose: minor aphtha.
Tcm diagnosis: flaming up of stomach-fire type.
Be attached at the affected part through giving the pharmaceutical composition paster, each 2, every day 2 times, ulcer surface healing after 4 days.Have a medical check-up: blood, two is just conventional, and electrocardiogram, liver function, kidney merit five change, in the drug administration process and think and not any reaction occurs.Treat the back integration: 0 minute.Efficacy determination is: clinical cure.
Above-mentioned clinical pre-test result shows: this pharmaceutical composition paster has eliminating damp-heat, and the effect of eliminating inflammation and expelling toxin is used for recurrent oral ulceration.Card sees that ulcer appears in oral mucosa, and with spontaneous pain, excitation pain, vexed irritability, mouthful hot xerostomia, yellowish urine dry stool etc.Treatment group disease total effective rate 100.00%, cure-remarkable-effectiveness rate 80.00%; Matched group disease total effective rate 90.00%, cure-remarkable-effectiveness rate 70.00%; Learning processing (P＜0.05) two groups by statistics has significant difference, and the treatment group is better than matched group.Clinical observation is not found untoward reaction and toxic and side effects therebetween.This medicine clinical practice safety is described, is applicable to recurrent oral ulceration.This medication is imitated reliable, takes, easy to carry, has no adverse reaction, and can be widely used in clinical.
Below by instantiation the preparation method that this pharmaceutical composition is made into various common formulations is described in further detail.
Embodiment 1: the tablet of pharmaceutical composition of the present invention
Prescription:
Component content
Hyperin 30.6g
Ampelopsin 9.8g
Quercetin 12.5g
Isoquercitrin 10.5g
Quercetin-3-O-α-L-rhamnose (1-6)-β-D-galactose 18.5g
Quercetin-3`-glucoside 20.6g
Starch 50g
Magnesium stearate 5g
With above-mentioned component mix homogeneously, adopt conventional pressed disc method, be pressed into 500.
Embodiment 2: the capsule of pharmaceutical composition of the present invention
Prescription:
Component content
Hyperin 29.5g
Ampelopsin 8.5g
Quercetin 13.6g
Isoquercitrin 11.2g
Quercetin-3-O-α-L-rhamnose (1-6)-β-D-galactose 19.8g
Quercetin-3`-glucoside 21.2g
Starch 70g
With above-mentioned component mix homogeneously, incapsulate in the shell, totally 500 capsules.
Embodiment 3: the granule of pharmaceutical composition of the present invention
Prescription:
Component content
Hyperin 32.3g
Ampelopsin 10.8g
Quercetin 13.2g
Isoquercitrin 11.6g
Quercetin-3-O-α-L-rhamnose (1-6)-β-D-galactose 17.8g
Quercetin-3`-glucoside 19.2g
Dextrin 110g
With above-mentioned component mix homogeneously, make granule, altogether 200g.
Embodiment 4: the injection of pharmaceutical composition of the present invention
Prescription:
Component content
Hyperin 28.5g
Ampelopsin 8.3g
Quercetin 11.6g
Isoquercitrin 9.2g
Quercetin-3-O-α-L-rhamnose (1-6)-β-D-galactose 17.6g
Quercetin-3`-glucoside 19.3g
Sodium chloride 8g
0.1mol/L hydrochloric acid is an amount of
Water for injection is added to 1000ml
With above-mentioned component mix homogeneously, be dissolved in the sodium-chloride water solution, add 0.1mol/L hydrochloric acid, regulate pH, add water to capacity again.
Embodiment 5: the oral liquid of pharmaceutical composition of the present invention
Prescription:
Component content
Hyperin 31.5g
Ampelopsin 10.3g
Quercetin 13.3g
Isoquercitrin 11.2g
Quercetin-3-O-α-L-rhamnose (1-6)-β-D-galactose 19.8g
Quercetin-3`-glucoside 21.6g
Ethyl hydroxybenzoate 0.5g
Distilled water adds 1000ml
With above-mentioned component mix homogeneously, 1000ml is made in dissolving.
Embodiment 6: the syrup of pharmaceutical composition of the present invention
Prescription:
Component content
Hyperin 32.3g
Ampelopsin 11.5g
Quercetin 13.6g
Isoquercitrin 12.0g
Quercetin-3-O-α-L-rhamnose (1-6)-β-D-galactose 19.0g
Quercetin-3`-glucoside 22.3g
Sodium benzoate 3g
Simple syrup adds to 1000ml
With above-mentioned component mix homogeneously, be dissolved to and make 1000ml in the simple syrup.
Embodiment 7: the ointment of pharmaceutical composition of the present invention
Prescription:
Component content
Hyperin 28.8g
Ampelopsin 8.5g
Quercetin 11.3g
Isoquercitrin 9.2g
Quercetin-3-O-α-L-rhamnose (1-6)-β-D-galactose 16.7g
Quercetin-3`-glucoside 18.6g
Liquid paraffin 60g
Tristerin 35g
Stearic acid 120g
White vaseline 10g
Lanoline 10g
Triethanolamine 4ml
Ethyl hydroxybenzoate 1g
Distilled water adds to 1000ml
With above-mentioned component mix homogeneously, be added in the oil-phase component that is heated to 80 ℃, fused oil phase is added aqueous phase, stir, make 1000g.
Embodiment 8: the gel of pharmaceutical composition of the present invention
Prescription:
Component content
Hyperin 28.5g
Ampelopsin 8.2g
Quercetin 10.6g
Isoquercitrin 9.3g
Quercetin-3-O-α-L-rhamnose (1-6)-β-D-galactose 16.8g
Quercetin-3`-glucoside 19.5g
Carbomer 10g
Ethanol 50g
Glycerol 50g
Polyoxyethylene sorbitan monoleate 2g
Ethyl hydroxybenzoate 1g
Sodium hydroxide 4g
Distilled water adds to 1000g
With above-mentioned component mix homogeneously, mix with carbomer and polyoxyethylene sorbitan monoleate and 300ml distilled water, sodium hydroxide is dissolved in adding behind the 100ml water to be gone up liquid and stirs evenly, again ethyl hydroxybenzoate is dissolved in ethanol after, add gradually and stir, promptly.
Embodiment 9: the paster agent of pharmaceutical composition of the present invention
Prescription:
Component content
Hyperin 32.5
Ampelopsin 10.2g
Quercetin 14.0g
Isoquercitrin 11.8g
Quercetin-3-O-α-L-rhamnose (1-6)-β-D-galactose 19.6g
Quercetin-3`-glucoside 22.5g
Hypromellose 45g
Carbomer 10g
Magnesium stearate 1g
Ethyl cellulose 30g
Lemon yellow color lake 45mg
With above-mentioned component mix homogeneously, add hypromellose and carbomer, mixing is granulated, and adds 1% magnesium stearate, and mixing is pressed into 2000, the compacting sealing coat, promptly.
Claims (8)
1. pharmaceutical composition is characterized in that this pharmaceutical composition contains the component of following consumption:
Hyperin 15～35 weight portions
Ampelopsin 1～15 weight portion
Quercetin 1～15 weight portion
Isoquercitrin 1～14 weight portion
Quercetin-3-O-α-L-rhamnose (1-6)-β-D-galactose 10～25 weight portions
Quercetin-3`-glucoside 8～25 weight portions.
2. according to the described pharmaceutical composition of claim 1, wherein the consumption of contained component is:
Hyperin 20～32 weight portions
Ampelopsin 4～13 weight portions
Quercetin 8～14 weight portions
Isoquercitrin 6～12 weight portions
Quercetin-3-O-α-L-rhamnose (1-6)-β-D-galactose 12～24 weight portions
Quercetin-3`-glucoside 15～22 weight portions.
3. according to the described pharmaceutical composition of claim 2, wherein the consumption of contained component is:
Hyperin 30 weight portions
Ampelopsin 9 weight portions
Quercetin 12 weight portions
Isoquercitrin 10 weight portions
Quercetin-3-O-α-L-rhamnose (1-6)-β-D-galactose 18 weight portions
Quercetin-3`-glucoside 21 weight portions.
4. arbitrary described pharmaceutical composition has tangible antiinflammatory in preparation in the claim 1～3, and is antibiotic, analgesia, and the promotion healing waits the purposes of the medicament of pharmacological actions.
In the claim 1～3 arbitrary described pharmaceutical composition in the purposes of the medicament of preparation treatment oral ulcer, gastric ulcer, burn and scald, trauma infection contamination (furuncle).
In the claim 1～3 arbitrary described pharmaceutical composition in the purposes of the medicament of preparation treatment oral ulcer and gastric ulcer.
7. arbitrary described pharmaceutical composition is treated the purposes that burn and scald injures the medicament of trauma infection contamination in preparation in the claim 1～3.
8. arbitrary described pharmaceutical composition can be made into various oral and exterior-applied formulations commonly used in the claim 1～3, comprises the preparation method of tablet, capsule, granule, injection, oral liquid, syrup, aerosol, paster agent, ointment, gel, patch, membrane etc.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200610008296A CN100594911C (en) | 2006-02-22 | 2006-02-22 | Medicine composition and use |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200610008296A CN100594911C (en) | 2006-02-22 | 2006-02-22 | Medicine composition and use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101023955A true CN101023955A (en) | 2007-08-29 |
| CN100594911C CN100594911C (en) | 2010-03-24 |
Family
ID=38742798
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200610008296A Active CN100594911C (en) | 2006-02-22 | 2006-02-22 | Medicine composition and use |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100594911C (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102579559A (en) * | 2012-03-31 | 2012-07-18 | 福建中医药大学 | Bauhinia championii ethyl acetate extract, n-butyl alcohol extract, and preparation methods and applications thereof |
| CN109432117A (en) * | 2019-01-07 | 2019-03-08 | 邱艳梅 | A kind of external drug and application thereof promoting postoperative skin wound healing |
| CN111991407A (en) * | 2020-04-16 | 2020-11-27 | 江苏苏中药业集团股份有限公司 | Application of isoquercitrin as inhibitor of calcium ion channel |
| CN111991408A (en) * | 2020-04-16 | 2020-11-27 | 江苏苏中药业集团股份有限公司 | Application of quercetin-3-O-robinin as inhibitor of calcium ion channel |
| CN112972485A (en) * | 2020-04-16 | 2021-06-18 | 江苏苏中药业集团股份有限公司 | Application of quercetin-3' -O-beta-D-glucoside as inhibitor of calcium ion channel |
-
2006
- 2006-02-22 CN CN200610008296A patent/CN100594911C/en active Active
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102579559A (en) * | 2012-03-31 | 2012-07-18 | 福建中医药大学 | Bauhinia championii ethyl acetate extract, n-butyl alcohol extract, and preparation methods and applications thereof |
| CN102579559B (en) * | 2012-03-31 | 2014-04-30 | 福建中医药大学 | Bauhinia championii ethyl acetate extract, n-butyl alcohol extract, and preparation methods and applications thereof |
| CN109432117A (en) * | 2019-01-07 | 2019-03-08 | 邱艳梅 | A kind of external drug and application thereof promoting postoperative skin wound healing |
| CN111991407A (en) * | 2020-04-16 | 2020-11-27 | 江苏苏中药业集团股份有限公司 | Application of isoquercitrin as inhibitor of calcium ion channel |
| CN111991408A (en) * | 2020-04-16 | 2020-11-27 | 江苏苏中药业集团股份有限公司 | Application of quercetin-3-O-robinin as inhibitor of calcium ion channel |
| CN112972485A (en) * | 2020-04-16 | 2021-06-18 | 江苏苏中药业集团股份有限公司 | Application of quercetin-3' -O-beta-D-glucoside as inhibitor of calcium ion channel |
| WO2021208985A1 (en) * | 2020-04-16 | 2021-10-21 | 江苏苏中药业集团股份有限公司 | USE OF QUERCETIN-3'-O-β-D-GLUCOSIDE AS CALCIUM CHANNEL INHIBITOR |
| CN111991407B (en) * | 2020-04-16 | 2022-09-13 | 苏中药业集团股份有限公司 | Application of isoquercitrin as inhibitor of calcium ion channel |
| CN111991408B (en) * | 2020-04-16 | 2022-10-28 | 苏中药业集团股份有限公司 | Application of quercetin-3-O-robioside as inhibitor of calcium ion channel |
| CN112972485B (en) * | 2020-04-16 | 2023-04-14 | 苏中药业集团股份有限公司 | Application of quercetin-3' -O-beta-D-glucoside as inhibitor of calcium ion channel |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100594911C (en) | 2010-03-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5502807B2 (en) | Colonic laxative composition comprising a soluble binder | |
| JP2755550B2 (en) | Pharmaceutical formulation containing rifaximin for treating gastric dyspepsia caused by Helicobacter pylori | |
| WO2006114061A1 (en) | A composition and method of regulating and maintaining the vaginal bacterial flora and the normal acidity in the vaginal | |
| KR20070028441A (en) | Oral antimicrobial pharmaceutical compositions | |
| KR20180033517A (en) | Mussel adhesive protein product, and its use for inhibiting mucosal inflammation | |
| CN100594911C (en) | Medicine composition and use | |
| JP2002525266A (en) | Taurolidine and / or taurultam for infectious ulcer or gastritis | |
| CN109758580A (en) | Treatment preparation and its application of injury to alimentary tract mucous membrane surface are sprayed to suitable for gastroscope | |
| CN103705525A (en) | Limonin-containing medicine for treating ulcerative colitis as well as preparation method and application thereof | |
| CN101507717B (en) | Composite tablet capable of treating peptic ulcer and preparation method thereof | |
| CN106146558A (en) | New oxazolidinones and preparation method thereof | |
| JP7189327B2 (en) | Composition for eradicating Helicobacter pylori | |
| CN104814964B (en) | A kind of pharmaceutical composition, the preparation method and applications of anti-stomach Helicobacter pylori | |
| CN101461832A (en) | Bioadhesive paster for treating mouth ulcer | |
| CN101721373B (en) | Solid cefdinir sub-microemulsion and application thereof | |
| CN100998576A (en) | Pharmaceutical preparation containing zinc baicalin | |
| CN101766813A (en) | Suppository for treating mammalian endometritis and preparation method thereof | |
| CN101708186A (en) | Application of arsenical sulphide, such as realgar and the like, in preparing medicine resisting malignant tumours and application of arsenical sulphide in preparing medicine resisting bacteria | |
| EA010241B1 (en) | Pharmaceutical compositions comprising ascorbic acid for the treatment of vaginal fungal infections | |
| CN105726491A (en) | Polyhexamethylene guanidine medicine for treating stomach disease and preparation method and application thereof | |
| KR20000022204A (en) | Preventives/remedies for stomatitis | |
| CN100425229C (en) | Local medicine preparation containing antiinfective medicine composition and its preparing method | |
| JP2000256212A (en) | Medicine for treating benign mesenchymoma | |
| CN104116732B (en) | A kind of application of andrographolide | |
| CN1030184A (en) | The manufacture method of anti-inflammation medicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C53 | Correction of patent of invention or patent application | ||
| CB03 | Change of inventor or designer information |
Inventor after: Ling Peixue Inventor after: Zhang Ling Inventor before: Ling Peixue Inventor before: Zhang Ling Inventor before: Liu Yanyan Inventor before: Zhao Chunrong |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: LING PEIXUE ZHANG LING LIU YANYAN ZHAO CHUNRONG TO: LING PEIXUE ZHANG LING |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20181221 Address after: 250101 989 Xinjie street, Ji'nan high tech Zone, Shandong Patentee after: SHANDONG ACADEMY OF PHARMACEUTICAL SCIENCES Address before: 250014 No. 264 Shanda Road, Lixia District, Jinan City, Shandong Province Patentee before: Ling Peixue |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20220826 Address after: Hangzhou City, Zhejiang province Binjiang District 310052 River Street No. 568 bin Kang Road Patentee after: HANGZHOU CONBA PHARMACEUTICAL Co.,Ltd. Address before: Xinluo Avenue high tech Zone of Ji'nan City, Shandong Province, No. 989 250101 Patentee before: SHANDONG ACADEMY OF PHARMACEUTICAL SCIENCES |